valu usd unless otherwis note
post-cal steal show
view beat rais driven legaci product
amgn row biosim launch highlight recent launch
disclosur surpris highlight deepen respons
registr trial updat model increas
headwind potenti margin compress reduc pt
remain sector perform rate
beat driven primarili legaci product pipelin
growth franchis continu commerci frustrat despit
beat/rais reduc dcf deriv price target
account margin compress come year
growth product commerci behind expect
highlight call could see excit
newli disclos updat iaslc sept barcelona see
overhang continu limit upsid stock oper
out-performance continu driven legaci product finit
commerci valu continu result price-to-earnings compress
limit valu recognit underscor enbrel beat
product whose futur far certain litig
sandoz play link enbrel ip analysi note eros sever
key base busi product underscor fragil amgn
base busi signific miss vs st sensipar q/q
declin vs st neulasta q/q declin
vs st sale sensipar declin
last two quarter respect growth product aimovig
repatha continu face competit headwind commerci concern
around potenti contribut meaning fill legaci product
eros amgn top-lin near term howev expect
excit around call given rapid progress toward
potenti registr trial set initi later year
updat model account report reduc pt
sh maintain sector perform rate
major highlight updat management
disclos activ addit tumor type combin
potenti registr trial nsclc could initi earli
year discuss respons recist two
addit tumor type colorect appendic cancer patient
call note plan clinic updat approach septemb
cont pg
price prior trade day market close estimate unless otherwis note
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view
trade appropri valu forward price-to-earnings basi vs
peer similar growth prospect discount project
revenu market product contribut
sh discount risk-adjust revenu pipelin product
contribut revenu contribut cash
contribut result price target
support sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
note potenti initi monotherapi portion program
management suggest could provid data futur regulatori file nsclc
identifi optim dose enrol patient dose level move
forward link note management note expans cohort highest dose
open recent seen flood patient enrol arm underscor
excit potenti kras-target therapi commun
margin compress becom emerg concern beyond management reiter
call oper expenditur expect increas back half
similar prior year due larg part increas rnd spend facilit expand
program margin compress expect headwind back
half see much room retreat opex face
at-risk top-lin blossom oncolog pipelin expens despit increas
excit see potenti concern emerg futur abil return
sharehold valu form stock buyback dividend increas rnd
expens go forward basi begin focu drive opportun
 pipelin forward quickli broadli possibl
aimovig show sign growth q/q declin script concern competit
cgrp market develop report aimovig sale increas
howev increas sale came despit flat-to-down quarter script
growth q/q rais concern demonstr potenti
convert signific number patient commerci reimburs prescript
vs may lose volume/pati competitor cgrp antibodi
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep
compani report capit market estim
incom base total product product product cost expens non oper incom ebit non incom tax tax net ep ep ep ep
compani report capit market estim
compani report capit market estim
dollar mm except per-shar data discount add add effect add termin businesskyprolisblincytorepathaparsabivevenityaimovigomecamtivbiosimilaroth revenuepric biotechnolog
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
